Palatin says King Pharma ends drug agreement on FDA concern

Sept 10 (Reuters) - Palatin Technologies Inc (PTN.A) said King Pharmaceuticals Inc (KG.N) ended its collaborative development agreement on bremelanotide used in the treatment of male erectile dysfunction and female sexual dysfunction.

Palatin said King Pharma exercised its right to terminate the deal after U.S. health regulators raised safety concerns about the efficacy of the results of the drug in early- and mid-stage trials.

(Reporting by Avishek Mishra in Bangalore)

((Editing by Amitha Rajan; Reuters Messaging: avishek.mishra.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: PALATIN AGREEMENT/KINGPHARMA

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS3707